These initiatives are not the only government decisions affecting pharma workers. "The biggest change in how we do business
is [the] Sarbanes-Oxley [Act]," says Allen Bokser, director of analytical R&D at Hollis-Eden Pharmaceuticals (San Diego, CA,
http://www.hollisedin.com/), a virtual biotech company that relies entirely on contract testing and manufacturing services. In many cases, that legislation
has resulted in extra documentation and extra time needed to complete routine tasks such as obtaining contracts and making
purchase orders, especially when conducting business with international service providers.
Figure 6: A steady, and almost predictable, increase in annual compensation continues to contribute to overall employment
stability and security.
The pharmaceutical industry continues to provide a stable job market. Overall, US respondents have continued to see a steady
increase in their annual salaries (see Figure 6), including a 5% increase over 2004. Women in aggregate continue to earn about
20% less than their male colleagues. Although there is a 6% increase in those who foresee a job change within the next 12
months, nearly 70% of all employees agree or strongly agree their jobs are secure.
1. US Department of Labor and the US Bureau of Labor Statistics "Highlights of Women's Earnings in 2004," report 987, Sept.
Photos courtesy of Sartorius Corporation.